Skip to main content
SpringerLink
Log in

Therapy-induced leukemias and myelodysplastic syndromes after breast cancer treatment: An underemphasized clinical problem

  • Original Articles
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Rowley J, Golomb H, Vardiman J. Nonrandom chromosomal abnormalities in acute leukemia and dysmyelopoietic syndromes in pateints with previously treated malignant disease.Blood 1977;50: 759–67.

    Google Scholar 

  2. Pedersen-Bjergaard J, Larson SO. Incidence of acute nonlymphocytic leukemia, preleukemia and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease.N Engl J Med 1982;307:965–71.

    Article  PubMed  CAS  Google Scholar 

  3. Levine EG, Bloomfield CD. Leukemias and myelodysplastic syndromes secondary to drug, radiation and environmental exposure.Semin Oncol 1992;19:47–84.

    PubMed  CAS  Google Scholar 

  4. Swinnen LJ. Diagnosis and treatment of transplant-related lymphoma.Ann Oncol 2000;11(Suppl 1):45–8.

    Article  PubMed  Google Scholar 

  5. Coleman CN, Williams CJ, Flint A, eta al. Hematologic neoplasia in pateints treated for Hodgkin's disease.N Engl J Med 1977;297: 1249–52.

    Article  PubMed  CAS  Google Scholar 

  6. Coleman CN, Kaplan HJ, Cox R. Leukemia, non-Hodgkin's lymphoma, and solid tumors in patients treated for Hodgkin's disease.Cancer Surv 1982;1:734–44.

    Google Scholar 

  7. Ballen KK, Antin JH. Treatment of therapy-related acute myelogenous leukemia and myelodysplastic syndromes.Hematol Oncol Clin North Am 1993;7:477–93.

    PubMed  CAS  Google Scholar 

  8. Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cel support in patients with potentially curable malignancies.J Cancer Res Clin Oncol 1998;124:207–14.

    Article  PubMed  CAS  Google Scholar 

  9. Teicher BA. Antitumor alkylating agents. In: DeVita VT, Hellman S, Rosenberg SH, eds.Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott-Raven, 1997:405–17.

    Google Scholar 

  10. Johnson JM, Ruddon RW. Interaction of nitrogen mustard with polyribonucleotide ribosomes and enzymes involved in protein synthesis in a cell free system.Mol Pharmacol 1967;3:195–203.

    PubMed  CAS  Google Scholar 

  11. Strauss BJ. Molecular biology of the response of cells to radiation and to radiomimetic chemicals.Cancer 1977;40:471–80.

    Article  PubMed  CAS  Google Scholar 

  12. Boice JD, Greene MH, Killen JY, eta al. Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU).N Engl J Med 1983;309:1079–84.

    Article  PubMed  Google Scholar 

  13. Blayney DW, Longo DL, Young RC, eta al. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease.N Engl J Med 1987;316:710–4.

    Article  PubMed  CAS  Google Scholar 

  14. Tucker MA, Coleman CN, Cox RS, eta al. Risk of second cancers after treatment for Hodgkin's disease.N Engl J Med 1988;318: 76–81.

    Article  PubMed  CAS  Google Scholar 

  15. Greene MH, Young RC, Merrill JM, DeVita VT. Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma.Cancer Res 1983;43:1891–8.

    PubMed  CAS  Google Scholar 

  16. Pedersen-Bjergaard J, Ersboll J, Sorensen HM, eta al. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents.Ann Intern Med 1985;103:195–200.

    PubMed  CAS  Google Scholar 

  17. Berk PD, Goldberg JD, Silverstein MN, eta al. Icreased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy.N Engl J Med 1981;304:441–7.

    Article  PubMed  CAS  Google Scholar 

  18. Bergsagel DE, Bailey AJ, Langley GR, eta al. The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia.N Engl J Med 1979;301:743–8.

    Article  PubMed  CAS  Google Scholar 

  19. Cuzick J, Erskine S, Edelman D, Galton DA. A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukemia in adults.Br J Cancer 1987;55:523–9.

    PubMed  CAS  Google Scholar 

  20. Pedersen-Bjergaard J, Nissen NI, Sorensen HM, eta al. Acute non-lymphocytic leukemia in patients with ovarian carcinoma following long-term treatment with treosulfan (=dihydroxybusulfan).Cancer 1980;45:19–29.

    Article  PubMed  CAS  Google Scholar 

  21. Greene MH, Harris EL, Gershenson DM, eta al. Melphalan may be a more potent leukemogen than cyclophosphamide.Ann Intern Med 1986;105:360–7.

    PubMed  CAS  Google Scholar 

  22. Stott H, Fox W, Girling DJ, eta al. Acute leukemia after busulfan.BMJ 1977;2:1513–7.

    PubMed  CAS  Google Scholar 

  23. Pedersen-Bjergaard J, Osterlind K, Hansen M, eta al. Acute nonlymphocytic leukemia, preleukemia, and solid tumors following intensive chemotherapy of small cell carcinoma of the lung.Blood 1985;66:1393–7.

    PubMed  CAS  Google Scholar 

  24. Fisher B, Rockette H, Fisher ER, eta al. Leukemia in breast cancer patients following adjuvant chemotherapy or postop radiation: the NSABP experience.J Clin Oncol 1985;12:1640–58.

    Google Scholar 

  25. Andersson M, Philip P, Pedersen-Bjergaard J. High risk therapy-related leukemia and preleukemia after therapy with prednimustine, methotrexate, 5-fluorauracil, mitoxantrone, and tamoxifen for advanced breast cancer.Cancer 1990;65:2460–4.

    Article  PubMed  CAS  Google Scholar 

  26. Curtis RE, Boice JD, Stovall M, eta al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer.N Engl J Med 1992;326:1745–51.

    Article  PubMed  CAS  Google Scholar 

  27. Karp JE, Smith MA. The molecular pathogenesis of treatment-induced (secondary) leukemias: foudations for treatment and prevention.Semin Oncol 1997;24:103–13.

    PubMed  CAS  Google Scholar 

  28. Auclerc G, Jacquillat C, Auclerc MF, eta al. Post-therapeutic acute leukemia.Cancer 1979;44:2017–25.

    Article  PubMed  CAS  Google Scholar 

  29. Smith MA, McCaffrey RP, Karp JE. The secondary leukemias: challenges and research directions.J Natl Cancer Inst 1996;88: 407–18.

    Article  PubMed  CAS  Google Scholar 

  30. Bennett JM, Catovsky D, Daniel MT, eta al. Proposals for the classification of the acute leukemias. French-American-Bristish (FAB) co-operative group.Br J Haematol 1976;33:451–8.

    PubMed  CAS  Google Scholar 

  31. Bennett JM, Catovsky D, Daniel MT, eta al. Proposed revised criteria for classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.Ann Intern Med 1985;103:620–5.

    PubMed  CAS  Google Scholar 

  32. Bennett JM, Catovsky D, Daniel MT, eta al. Criteria for the diagnosis of acute myelogenous leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group.Ann Intern Med 1985;103:460–2.

    PubMed  CAS  Google Scholar 

  33. Bennett JM, Catovsky D, Daniel MT, eta al. Proposal for the recognition of minerally differentiated acute myeloid leukemia (AML-M0).Br J Haematol 1991;78:325–9.

    PubMed  CAS  Google Scholar 

  34. Pedersen-Bjergaard J, Phillip P, Larsen SO, eta al. Chromosome aberrations and prognostic factors in therapy-related myelodysplastic and acute nonlymphocytic leukemia.Blood 1990;76:1083–91.

    PubMed  CAS  Google Scholar 

  35. Kantarjian HM, Keating MJ, Walters RS, eta al. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic and prognostic factors.J Clin Oncol 1986;4:1748–57.

    PubMed  CAS  Google Scholar 

  36. LeBeau MM, Albain KS, Larson RA, eta al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosome numbers 5 and 7.J Clin Oncol 1986;4:325–45.

    CAS  Google Scholar 

  37. Misra NC, Roberts D. Inhibition by 4′-dmethyl-epipodophyllotoxin 9-(4,6-O-L-thenylidene-beta-D-glucopyranoside) of human lymphoblast cultures in G2 phase of the cell cycle.Cancer Res 1975;35:99–105.

    PubMed  CAS  Google Scholar 

  38. Krishan A, Paika K, Frei E. Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts.J Cell Biol 1975:66:521–30.

    Article  PubMed  CAS  Google Scholar 

  39. Ross W, Rowe T, Glisson B, eta al. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage.Cancer Res 1984;44:5857–60.

    PubMed  CAS  Google Scholar 

  40. Blum RH, Carter SK. Adriamycin. A new anticancer drug with significant clinical activity.Ann Intern Med 1974;80:249–59.

    PubMed  CAS  Google Scholar 

  41. Robert J, Gianni L. Pharmacokinetics and metabolism of anthracyclines.Cancer Surv 1993;17:219–52.

    PubMed  CAS  Google Scholar 

  42. Corbett AH, Osheroff N. When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs.Chem Res Toxicol 1993;6:585–97.

    Article  PubMed  CAS  Google Scholar 

  43. Tewey KM, Rowe TC, Yang L, eta al. Adriamycin-induced DNA cleavage mediated by mammalian DNA topoisomerase II.Science 1984;226:466–8.

    Article  PubMed  CAS  Google Scholar 

  44. Driscoll JS, Hazard GF, Wood HB, Goldin A. Structure-antitumor activity relationships among quinone derivatives.Cancer Chemother Rep 2 1974;4:1–362.

    CAS  Google Scholar 

  45. Handa K, Sato S. Stimulation of microsomal NADPH oxidation by quinone group-containing anticancer chemicals.Gann 1976;67: 523–8.

    PubMed  CAS  Google Scholar 

  46. Ratain MJ, Kaminer LS, Bitran JD, eta al. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung.Blood 1987;70:1412–7.

    PubMed  CAS  Google Scholar 

  47. Pui CH, Behm FG, Ranimondi SC, eta al. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia.N Engl J Med 1989;321:136–42.

    Article  PubMed  CAS  Google Scholar 

  48. DeVore R, Whitlock J, Hainsworth JD, Johnson DH. Therapy-related acute nonlymphocytic leukemia with monocytic features and rearrangements of chromosome 11q.Ann Intern Med 1989; 110:740–2.

    PubMed  CAS  Google Scholar 

  49. Yagita M, Ieki Y, Onishi R, eta al. Therapy-related leukemia and myelodysplasia following oral administration of etoposide for recurrent breast cancer.Int J Oncol 1998;1:91–6.

    Google Scholar 

  50. Smith M, Rubinstein L, Cazenave L, eta al. Report of the Cancer Therapy Evaluation Program monitoring plan for secondary acute myeloid leukemia following treatment with epipodophyllotoxins.J Natl Cancer Inst 1993;85:554–8.

    Article  PubMed  CAS  Google Scholar 

  51. Smith M, Rubinstein L, Anderson JR, eta al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins.J Clin Oncol 1999;17:569–77.

    PubMed  CAS  Google Scholar 

  52. Domer PH, Head DR, Renganathan N, eta al. Molecular analysis of 13 cases of MLL/11q23 secondary acute leukemia and identification of topoisomerase II consensus-binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4∶11).Leukemia 1995;9:1305–12.

    PubMed  CAS  Google Scholar 

  53. Hunger SP, Tkachuk DC, Amylon MD, eta al. HRX involvement in de novo and secondary leukemias with diverse chromosome 11q23 abnormalities.Blood 1993;81:3197–202.

    PubMed  CAS  Google Scholar 

  54. Djabali M, Salleri L, Parry P, eta al. A trithorax-like gene is interupted by chromosome 11q23 translocations in acute leukemia.Nat Genet 1992;2:113–8.

    Article  PubMed  CAS  Google Scholar 

  55. Larson RA, LeBeau MM, Ratain MJ, Rowley JD. Balanced translocations involving chromosome band 11q23 and 21q22 in therapy-related leukemia.Blood 1992;79:1892–3.

    PubMed  CAS  Google Scholar 

  56. Pedersen-Bjergaard J, Phillip P. Balanced translocations involving chromosome band 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA topoisomerase II.Blood 1991;78:1147–8.

    PubMed  CAS  Google Scholar 

  57. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells.Proc Natl Acad Sci 1980;77:1561–5.

    Article  PubMed  CAS  Google Scholar 

  58. Rowinsky EK, Donehower RC, Jones RJ, Tucker RW. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol.Cancer Res 1988;48:4093–100.

    PubMed  CAS  Google Scholar 

  59. Seymour JF, Juneja SK, Campbell LJ, eta al. Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy.Leukemia 1999;13:1735–40.

    Article  PubMed  CAS  Google Scholar 

  60. MacGregor JI, Jordan VC. Basic guide to the mechanism of antiestrogen action.Pharmacol Rev 1998;50:151–96.

    PubMed  CAS  Google Scholar 

  61. Sutherland RL, Redel RR, Murphy LC, Taylor IW. Effects of antiestrogens on cell cycle progression. In: Jordan VC, ed.Estrogen/Antiestrogen Action and Breast Cancer Therapy. Madison, WI: University of Wisconsin Press, 1986:235–81.

    Google Scholar 

  62. Love RR. Antiestrogens as chemopreventive agents in breast cancer: promise and issues in evaluation.Prev Med 1989;18:661–71.

    Article  PubMed  CAS  Google Scholar 

  63. Rutquist LE, Johansson H, Signomklao T, eta al. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group.J Natl Cancer Inst 1995;87:645–51.

    Article  Google Scholar 

  64. Yalcin S, Gullu I, Demiroglu H, Tekuzman G. Acute leukemia during tamoxifen therapy.Med Oncol 1997;14:61–2.

    Article  PubMed  CAS  Google Scholar 

  65. Little JB. Cellular, molecular, and carcinogenic effects of radiation.Hematol Oncol Clin North Am 1993;7:337–52.

    PubMed  CAS  Google Scholar 

  66. Terasima R, Tolmach LI. X-ray sensitivity abd DNA synthesis in synchronous populations of Hela cells.Science 1963;140:490–2.

    Article  PubMed  CAS  Google Scholar 

  67. Sinclair WK, Morton RA. X-ray sensitivity during cell generation cycle of cultured Chinese hamster ovary cells.Radiat Res 1966; 29:450–74.

    Article  PubMed  CAS  Google Scholar 

  68. Madoc-Jones H, Mauro F. Age response to x-rays, vinca alkaloids and hydroxyurea of murine lymphoma cells synchronized in vivo.J Natl Cancer Inst 1970;45:1131–43.

    PubMed  CAS  Google Scholar 

  69. Hellman S. Cell kinetics, models, and cancer treatment: some principles for the radiation oncologist.Radiology 1975;114:219–23.

    PubMed  CAS  Google Scholar 

  70. Hellman S. Principles of cancer management: radiation therapy. In: DeVita V, Hellman S, Rosenberg S, eds.Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott-Raven 1997:307–32.

    Google Scholar 

  71. Epstein R, Hanham I, Dale R. Radiotherapy-induced second cancers: are we doing enough to protect young patients?Eur J Cancer 1997;33:526–30.

    Article  PubMed  CAS  Google Scholar 

  72. Boice JD, Blettner M, Kleinerman RA, eta al. Radiation dose and leukemia risk in patients treated for cancer of the cervix.J Natl Cancer Inst 1987;79:1295–311.

    PubMed  Google Scholar 

  73. Boivin JF, Hutchison GB, Evans FB, eta al. Leukemia after radiotherapy for first primary cancers of various anatomic sites.Am J Epidemiol 1986;123:993–1003.

    PubMed  CAS  Google Scholar 

  74. Curtis RE, Hanley BF, Meyers MH, Young JL. Risk of leukemia associated with the first course of cancer treatment: an analysis of the Surveillance, Epidemiological, and End Results Program experience.J Natl Cancer Inst 1984;72:531–44.

    PubMed  CAS  Google Scholar 

  75. Curtis RE, Boice JD, Stovall M, eta al. Leukemia risk following radiotherapy for breast cancer.J Clin Oncol 1989;7:21–9.

    PubMed  CAS  Google Scholar 

  76. Lavey RS, Eby NL, Prosmitz LR. Impact of radiation therapy and/or chemotherapy on the risk for a second malignancy after breast cancer.Cancer 1990;66:874–81.

    Article  PubMed  CAS  Google Scholar 

  77. Pedersen-Bjergaard J. Radiation- and chemotherapy-induced myelodysplasia and acute myeloid leukemia. A review.Leuk Res 1992;16:61–5.

    Article  PubMed  CAS  Google Scholar 

  78. Sobeck RM, Beau MML, Anastasi J, Williams SF. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stern cell transplantation.Bone Marrow Transplant 1999;23:1161–5.

    Article  Google Scholar 

  79. Laughlin MJ, McGaughey DS, Crews JR, eta al. Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplantation.J Clin Oncol 1998;16: 1008–12.

    PubMed  CAS  Google Scholar 

  80. Roman-Unfer S, Bitran JD, Hanauer S, eta al. Acute myeloid and myelodysplasia following intensive chemotherapy for breast cancer.Bone Marrow Transplant 1995;16:163–8.

    PubMed  CAS  Google Scholar 

  81. Tallman MS, Gray R, Bennett JM, eta al. Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience.J Clin Oncol 1995;13: 1557–63.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Derpatment of Pharmacology, The Tulane Center, New Orleans, Louisiana

    Christopher B. Weldon MD, PhD

  2. Department of Medicine, The Tulane Cancer Center, New Orleans, Louisiana

    Marc J. Kahn MD

  3. Department of Surgery, Tulane University School of Medicine, 1430 Tulane Avenue, SL-22, 70112, New Orleans, LA

    Christopher B. Weldon MD, PhD & Bernard M. Jaffe MD

Authors
  1. Christopher B. Weldon MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bernard M. Jaffe MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marc J. Kahn MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernard M. Jaffe MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weldon, C.B., Jaffe, B.M. & Kahn, M.J. Therapy-induced leukemias and myelodysplastic syndromes after breast cancer treatment: An underemphasized clinical problem. Annals of Surgical Oncology 9, 738–744 (2002). https://doi.org/10.1007/BF02574495

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02574495

Key Words

Search

Navigation